{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-007404","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.663231+00:00","generated_at":"2026-06-16T04:46:22.139487+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aytu BioPharma subleases 22,909 sq ft of manufacturing facility to AMTMS; to expand to entire facility by Dec 2024","bullets":["Subleases 22,909 sq ft (~30%) of Grand Prairie, TX facility to AMTMS; base rent $20,045/mo through Dec 2023, then $21,000/mo until expansion.","Expansion to entire 77,112 sq ft facility by Dec 31, 2024; rent rises to $70,686/mo. Security deposit of $90,731.","CEO says sublease reduces monthly operating expenses, supports margin improvement for ADHD products; longer-term plan to transfer manufacturing to contract manufacturer.","AMTMS is a new CMO; will use facility for nutraceutical and pharmaceutical manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-007404","json":"https://secwatch.observer/filing/0001558370-23-007404.json","markdown":"https://secwatch.observer/filing/0001558370-23-007404.md","text":"https://secwatch.observer/filing/0001558370-23-007404.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023007404/0001558370-23-007404-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023007404/aytu-20230427x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T04:46:22.139487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30c8ca70dda3467473bef45480a4fcbda0f89815","claim":"AYTU BIOPHARMA, INC entered into Sublease Agreement with AMT Manufacturing Solutions, LLC (effective 2023-04-27).","evidence_excerpt":"On April 27, 2023, Aytu BioPharma, Inc., through its wholly-owned subsidiary, Neos Therapeutics, LP, (“Aytu” or the “Company”) and AMT Manufacturing Solutions, LLC (“AMTMS”) entered into an agreement for Aytu to sublease 22,909 square feet of its manufacturing facility in Grand Prairie, Texas (“Sublease Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023007404/0001558370-23-007404-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"lease"},{"label":"Counterparty","value":"AMT Manufacturing Solutions, LLC"},{"label":"Effective","value":"2023-04-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}